Glucosamine Supplements may be Linked to Lower Risk of Cardiovascular Disease: Study

Glucosamine may have benefits in preventing CVD events, such as coronary heart disease and stroke, and further clinical trials are needed to test this theory.

A new study has found that regular use of glucosamine supplements may be associated with a lower risk of cardiovascular disease (CVD) events, suggested an analysis of data from the UK Biobank study, published in The BMJ today.//

Glucosamine is a popular dietary supplement used to relieve osteoarthritis and joint pain. While its effectiveness on joint pain continues to be debated, emerging evidence suggests that glucosamine may have a role in preventing cardiovascular disease and reducing mortality. However, conclusive evidence is still lacking

PLAC Test for Cardiovascular Disease
Ensure your heart health by getting a PLAC test. Prevent heart attack and stroke by detecting your risk of developing cardiovascular disease.

‘Glucosamine may have benefits in preventing CVD events, such as coronary heart disease and stroke, and further clinical trials are needed to test this theory, said researchers. ’

So to explore these potential associations further, researchers led by Professor Lu Qi at Tulane University in New Orleans drew on data from the UK Biobank - a large population based study of more than half a million British men and women.

Their analysis included 466,039 participants without CVD, who completed a questionnaire on supplement use, including glucosamine.

Death certificates and hospital records were then used to monitor CVD events, including CVD death, coronary heart disease (CHD), and stroke, over an average seven-year follow up period.

Stroke Risk Calculator
Stroke Risk Calculator checks if you have hypertension, diabetes and heart failure and predicts the risk of stroke (cerebrovascular accident) in next 10 years.

Overall, almost one in five (19.3%) participants reported glucosamine use at the start of the study.

The researchers found that glucosamine use was associated with a 15% lower risk of total CVD events, and a 9% to 22% lower risk of CHD, stroke, and CVD death compared with no use.

Quiz on Healthy Heart
Heart disease is a major killer worldwide in spite of major strides in the medical field in terms of research, diagnosis, treatment and pharmacology. HIV/AIDS and Alzheimer’s disease are vying for popular attention these days and people tend to sideline or neglect healthy heart awareness. Take our quiz and refresh your awareness on heart disease.

These favourable associations remained after taking account of traditional risk factors, including age, sex, weight (BMI), ethnicity, lifestyle, diet, medication and other supplement use.

The association between glucosamine use and CHD was also stronger in current smokers (37% lower risk) compared with never (12%) and former smokers (18%).

By Mimicking a Low-Carb Diet, Glucosamine Promotes Longevity
For many decades, glucosamine has been freely available in drugstores, it is widely used to treat arthritis and to prevent joint degeneration.

Several mechanisms may explain these results, say the authors. For example, regular use of glucosamine has been linked to a reduction in levels of C-reactive protein (CRP), a chemical associated with inflammation. This may also help to explain the stronger association among smokers, who have higher levels of inflammation and higher risk of CVD than non-smokers.

In addition, previous data suggest that glucosamine may mimic a low carbohydrate diet, which has been inversely associated with the development of CVD.

Despite the large sample size, this is an observational study, and as such, can't establish cause, and the researchers point to some limitations, such as lack of information on dose, duration, and side effects of glucosamine use.

Regular glucosamine use may also be a marker for a healthy lifestyle, they add, but this is unlikely to have affected the results.

As such, they conclude that "habitual use of glucosamine supplements to relieve osteoarthritis pain might also be related to lower risks of CVD events. Further clinical trials are warranted to test this hypothesis."

Source-Eurekalert